Loss of Gadd45b accelerates BCR-ABL-driven CML

Xiaojin Sha; Barbara Hoffman; Dan A. Liebermann

doi:10.18632/oncotarget.26076

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Loss of Gadd45b accelerates BCR-ABL-driven CML

Xiaojin Sha _, Barbara Hoffman and Dan A. Liebermann

PDF | HTML | How to cite

Oncotarget. 2018; 9:33360-33367. https://doi.org/10.18632/oncotarget.26076

Metrics: PDF 2190 views | HTML 2358 views | ?

Abstract

Xiaojin Sha1,*, Barbara Hoffman1,* and Dan A. Liebermann1,2

1Fels Institute for Cancer Research and Molecular Biology, Temple University, Philadelphia, PA, USA

2Department of Medical Genetics and Molecular Biochemistry, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA

*These authors have contributed equally to this work

Correspondence to:

Dan A. Liebermann, email: [email protected]

Keywords: Gadd45a; chronic myelogenous leukemia; stress response protein; tumor suppressor

Received: July 23, 2018 Accepted: July 28, 2018 Published: September 07, 2018

ABSTRACT

Gadd45b is a member of Gadd45 stress sensor protein family that also includes Gadd45a and Gadd45g. To investigate the effect of Gadd45b in bcr-abl oncogene driven chronic myeloid leukemia (CML) development, syngeneic wild type lethally irradiated mice were reconstituted with either wild type or Gadd45b null myeloid progenitors transduced with a retroviral vector expressing BCR-ABL. Loss of Gadd45b was observed to accelerate BCR-ABL driven CML development with shortened median mouse survival time. BCR-ABL Gadd45b deficient CML progenitors exhibited increased proliferation and decreased apoptosis, associated with hyper-activation of c-Jun NH₂-terminal kinase and Stat5. These results provide novel evidence that gadd45b, like gadd45a, functions as a suppressor of BCR-ABL driven leukemia, albeit via a different mechanism.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26076

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Loss of Gadd45b accelerates BCR-ABL-driven CML

Abstract